Liminatus Pharma, Inc.
No enriched coverage for $LIMN in the last 7 days.
No SEC Form 4 filings for $LIMN in the last 30 days.
See all $LIMN insider activity →Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule FULLERTON, Calif., September 29, 2026 – Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid pric
Liminatus Pharma Inc. (LIMN) engaged Synex Consulting to advance its cancer therapy IBC101, acquired through a $320M deal. The therapy received South Korea's approval for a Phase 1/2a study. Liminatus faces Nasdaq listing challenges, recently transferred to the Nasdaq Capital Market, and completed a 1-for-50 reverse stock split. Shares fell 29% since the split.
Liminatus Pharma partners with Synex Consulting to advance its CAR-T cell therapy in South Korea. The Ministry of Food and Drug Safety authorized a Phase 1/2a clinical study. Liminatus went public via a SPAC last year. Shares are down 8.2% to $4.73, with a $6.4M market cap.
Recent LIMN coverage spans corporate actions, mergers & acquisitions and technology.
Compliance regain removes delisting risk and may support price stability.
The split reduces float and may trigger short covering, but ongoing delisting risk adds downside pressure.
The new collaboration may accelerate clinical development in South Korea but the immediate market reaction was negative, suggesting short‑term sell pressure.
Nasdaq listing/compliance extension is a near-term overhang removal catalyst that can sustain momentum into the open.
The Nasdaq tier transfer and compliance extension reduce near-term delisting risk, but keep the bid-price overhang active through the new deadline.
AlphAI scores every news story that mentions LIMN with an AI model for sentiment and relevance, and aggregates insider trades from Liminatus Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule FULLERTON, Calif., September 29, 2026 – Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid pric
1 min readLiminatus Pharma Inc. (LIMN) engaged Synex Consulting to advance its cancer therapy IBC101, acquired through a $320M deal. The therapy received South Korea's approval for a Phase 1/2a study. Liminatus faces Nasdaq listing challenges, recently transferred to the Nasdaq Capital Market, and completed a 1-for-50 reverse stock split. Shares fell 29% since the split.
2 min readLiminatus Pharma partners with Synex Consulting to advance its CAR-T cell therapy in South Korea. The Ministry of Food and Drug Safety authorized a Phase 1/2a clinical study. Liminatus went public via a SPAC last year. Shares are down 8.2% to $4.73, with a $6.4M market cap.
2 min readIn biotech pre-market trading, Liminatus Pharma (LIMN) rose about 72% after moving to Nasdaq Capital and receiving an extension to regain minimum bid-price compliance. Iveda Solutions (IVDA) gained about 30% on a partnership announcement with GlobalMed. LENSAR (LNSR) was up about 22% after reporting second-quarter results.
2 min readLiminatus Pharma (Nasdaq: LIMN) said its shares transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective Aug. 4, 2026, keeping the ticker LIMN. Nasdaq’s Hearings Panel granted an extension to regain compliance with the minimum bid price rule, with a deadline of Sept. 3, 2026.
2 min readLiminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 3, 2026, Liminatus Pharma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The holders of 32,446,373 shares of common stock, or approximately 48.31% of the outstandi
2 min readLiminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha
3 min readLiminatus Pharma (NASDAQ:LIMN) shares rose 30.49% to $0.15 in after-hours after the company amended and restated its merger agreement with InnocsAI LLC. The revised terms aim to let the deal close before shareholder approval, expected Thursday, with consideration valued at $0.20 per share plus contingent value rights.
3 min readLiminatus Pharma (LIMN) amended its merger agreement with InnocsAI LLC to expand its oncology pipeline. The deal is now expected to close July 2, 2026, before stockholder approval. InnocsAI holders will receive Liminatus common stock and newly designated non-voting convertible preferred issued at $0.20/share, implying ~$320M value, plus CVRs on 20% of future net proceeds.
4 min readLiminatus Pharma, Inc. (NASDAQ: LIMN), a pre-clinical stage immuno-oncology company, announced the pricing of a public offering expected to raise approximately $4.0 million in gross proceeds. The offering includes 13,813,000 shares (or pre-funded warrants) and warrants to purchase up to 20,719,500 shares, at a combined price of $0.29 per share. The company plans to use the net proceeds for working capital, general corporate purposes, and advancing its business objectives.
2 min read
